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S U M M A R Y
Objective: The aim of this study was to determine the prevalence of tuberculosis (TB) in adolescents in
western Kenya.
Methods: A cohort study of 5004 adolescents aged 12–18 years was conducted. Adolescents were
screened for prevalent TB using clinical criteria, history of TB contact, and a Mantoux test. Cases of
suspected TB were investigated through two sputum examinations (microscopy and liquid culture) and
chest radiography.
Results: Out of 5004 adolescents enrolled, 1960 (39.2%) were identiﬁed with suspected TB, including
1544 with a positive Mantoux (prevalence 1544/4808, 32.1%), 515 with symptoms suggestive of TB
(10.3%), and 144 (2.9%) with household TB contact. Sixteen culture-conﬁrmed (deﬁnite) and 18 probable
pulmonary TB (PTB) cases were identiﬁed, reﬂecting a prevalence estimate of 3.2/1000 (deﬁnite) and 6.8/
1000 all PTB, respectively. Only one smear-positive case was detected. The case notiﬁcation rate among
12–18-year-old adolescents for all TB was 101/100 000, yielding a patient diagnostic rate of 0.13 (95%
conﬁdence interval 0.03–3.7) cases detected per person-year for all TB.
Conclusion: The prevalence of PTB among adolescents is high, with the majority of cases not detected
routinely. Innovative active case ﬁnding including the wider use of Xpert MTB/RIF is needed to detect
smear-negative TB among adolescents.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) has been declared a global health emergency
by the World Health Organization (WHO).1 No current vaccine has
been shown to reliably prevent pulmonary TB in adolescents.2 The
risk of TB disease increases steeply in adolescence, suggesting
adolescents may be a suitable target group for vaccination.3,4 New
vaccines are currently being developed,5–7 and adolescents are
considered a convenient target for novel TB vaccine trials because§ The work presented in this paper was performed under the KEMRI and CDC
Collaboration in western Kenya.
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).they are easy to reach in schools, are not highly mobile, and do not
have many of the comorbidities that exclude adults from trial
participation. These trials will be conducted in areas with a high
burden of TB disease.
In order to assess the potential for TB vaccine trials among
adolescents and build staff capacity, an incidence cohort study was
conducted in western Kenya. In this paper, we report TB prevalence
at intake of the study cohort.
The WHO reported 8.7 million new cases of TB globally in 2012,
of which 0.5 million were in children aged less than 15 years, and
26% of those cases occurred in the Africa region.8 Kenya reported
103 981 new cases in 2011, with only 6% of those occurring in
children under 15 years of age. In the lesser Siaya District, where
the study took place, 795 TB cases were registered in 2011, of
which 43 (5.4%) were in adolescents aged 12–18 years, equivalentciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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smear-positive. Overall reported rates of TB in the study area were
approximately 521 per 100 000 population, similar to overall
notiﬁcation rates in Nyanza Province in 2010.9 HIV prevalence in
15–19-year-olds in Kenya is estimated to be 1.7% according to the
Kenya Demographic and Health Survey 2009.10
A recent prevalence survey among adults conducted in the
same study area reported a TB prevalence among 15–24-year-olds
of 3.7 per 1000 (95% conﬁdence interval (CI) 2.2–6.2) among
females and 1.8 per 1000 (95% CI 0.8–4.2) among males.11,12 This
prevalence survey used a screening algorithm for adults using
symptoms and chest X-rays as primary screening tools.12 The
present study enrolled a younger cohort (aged 12–18 years),
primarily composed of youth enrolled in school. Moreover, in order
to limit the use of chest radiography, testing for latent TB infection
was added as a screening tool to identify those with suspected TB.
The aim of this analysis was to determine the burden of TB
among adolescents. Some of the interim results of this study have
been reported previously in an abstract.13
2. Methods
2.1. Study setting
The Kenya Medical Research Institute (KEMRI)/Centers for
Disease Control and Prevention (CDC) Research and Public Health
Collaboration, operates a health and demographic surveillance
system (HDSS) in the study area. The HDSS provides general
demographic and health information (such as population age,
structure, density, fertility rates, birth rates, in- and out-migrations,
geographic information system (GIS) coordinates, patterns of health
care access and utilization, and the local economics of health care), as
well as disease- and intervention-speciﬁc information.14
2.2. Study design and population
A cross-sectional survey was conducted at enrolment into an
observational cohort study of adolescents aged 12–18 years living
in Karemo Division, Siaya District, Nyanza Province, in western
Kenya. Karemo is predominantly rural, and the majority of
residents are small-scale farmers and of Luo ethnicity. The study
area covered approximately 11 000 adolescents aged 12–18 years
and was divided into 17 clusters of approximately equal
population size, each containing a school. Nine of these clusters
were selected randomly.
Before enrolment commenced in any cluster, personal digital
assistants (PDAs) were preloaded with a cluster-speciﬁc HDSS
database containing information on villages, compounds, and
households in which eligible adolescents resided. All adolescents
residing in a cluster were approached to participate in the study if
they met the study’s residency deﬁnition. Trained ﬁeld workers
identiﬁed households with adolescents with the help of commu-
nity volunteers called village reporters. While the HDSS deﬁnes
residents as persons who have lived in the HDSS area for at least
4 months, in this study, we included adolescents who had lived in
the area for at least 1 month. All enrolled adolescents who did not
meet the HDSS resident criteria were categorized as new residents.
2.3. Consenting
Parents of eligible adolescents were informed and invited to
consent; minor assent was also sought from adolescents aged
12–17 years. Mature minors (married, pregnant, or having
delivered a baby, or the head of a household)15,16 and
adolescents aged 18 years were requested to give their own
independent consent. Thereafter, the parents/guardians andthe eligible adolescents were invited to a mobile ﬁeld site (MFS)
consisting of several tents, a ﬁeld-based computer server,
laptops for data entry, a generator, and a mobile chest X-ray
truck located in a nearby school, for enrolment into the study.
2.4. TB screening
Adolescents were evaluated at enrolment for symptoms of
possible TB, deﬁned as one or more of the following: cough for 2
weeks, weight loss for 2 weeks, fever for 2 weeks, night sweats
for 2 weeks, or hemoptysis and exposure to TB, deﬁned as living
in a household where a person had been diagnosed with TB.
Participants were queried about clinical and TB treatment history
within the last 6 months and/or diagnosis of acute or chronic
diseases. Demographic characteristics (e.g., parent/guardian occu-
pations, education, and income, and participant’s gender and date
of birth (DOB)) were also collected during the interview and
reviewed with the study participant.
All participants (except those currently on TB treatment) had a
tuberculin skin test (TST) administered by the Mantoux technique
using PPD RT23 (Statens Serum Institut, Denmark). The test was
read 48–72 h after administration (92%), but late readings were
included up to a maximum of 7 days. A Mantoux test result of
10 mm in HIV-negatives/those with unknown HIV status, or
5 mm in HIV-positives, was considered positive. Participants
with a positive TST, household contact with a TB case in the
previous 2 years, or the presence of at least one TB symptom, were
asked to provide a spot and early morning sputum and to undergo
chest X-ray examination. They were also offered HIV testing.
2.5. Chest X-ray interpretation
Chest X-rays were read by clinical ofﬁcers trained in using the
chest radiograph reading and recording system (CRRS) method,
immediately after the radiograph was obtained.17 Subsequently a
CRRS certiﬁed medical ofﬁcer reviewed the chest X-rays before a
ﬁnal decision on subject management was made. All chest X-rays
classiﬁed as abnormal and a subset of 10% of those read as normal
were reviewed by a CRRS certiﬁed expert and their opinion was
taken to be ﬁnal in regard to the ﬁnal interpretation of the chest
X-ray.
2.6. Laboratory analyses
Expectorated sputa were digested using Nalc NaOH and
concentrated by centrifugation. Digested sputa were inoculated
into solid (Lowenstein–Jensen) and liquid (MGIT 960) culture
media and examined for acid-fast bacilli (AFB) by ﬂuorescence
microscopy (FM). Positive cultures were conﬁrmed as AFB by
Ziehl–Neelsen (ZN) staining and speciated with either the Capilia
(FIND and Tauns Co. Ltd) or GenoType assay (Hain Diagnostika,
Nehren, Germany). Laboratory cross-contamination rates were
monitored through processing anonymized artiﬁcial sputum as
part of study specimens and analyzing the growth of Mycobacteri-
um tuberculosis in the TB culture laboratory. At the beginning of the
project, sputum samples were stained for FM in a distant
laboratory. Due to delays in reading a portion of the FM slides,
the ﬂorescence was lost and the slides were re-stained with ZN
stain to reconﬁrm smear negativity.
2.7. TB treatment
Adolescents identiﬁed with active TB were referred to a
Ministry of Health TB clinic for TB treatment. Adolescents with
HIV were referred for evaluation for HIV care and treatment
services at the Patient Support Centre (PSC) nearest to their homes.
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The sample size was determined on the basis of an estimate of
active TB incidence, which was estimated at 4 per 1000. Thus, a
sample of 5000 adolescents would yield a 95% CI on this estimate of
2.4–6.2 per 1000, based on a Poisson distribution.
2.9. Case deﬁnition
A deﬁnite case of TB disease was deﬁned as two or more smears
positive for AFB or one positive culture conﬁrmed by speciation. A
probable case was deﬁned as any pulmonary case diagnosed by a
clinician through clinical symptoms and radiographic abnormali-
ties to be consistent with active TB, who did not meet the criteria
for a deﬁnite case. Participants with only one positive smear were
classiﬁed as probable TB cases only if they met the clinical
deﬁnition of TB. Participants with previous TB were only classiﬁed
as a TB case if they had deﬁnite TB, since their symptoms, positive
TST, and chest X-ray abnormalities might be attributable to their
previous TB episode.
2.10. Data analysis
The prevalence of TB was calculated and adjusted for clustering
using survey procedures for SAS version 9.1 (SAS Institute Inc.,Figure 1. Participant enrolmCary, NC, USA). Risk factors for prevalent TB were explored with
bivariate analysis. The case detection rate is the number of
reported cases per 100 000 persons per year divided by the
estimated incidence rate per 100 000 per year. TB incidence is
uncertain and not measured but estimated; therefore, the case
detection rate is uncertain. The patient diagnostic rate (PDR),
which is the rate at which prevalent cases are detected by TB
control programs, was calculated by dividing the number of all
new TB cases per 100 000 among those aged 12–18 years notiﬁed
by the TB program, by the prevalence of TB per 100 000 in the same
age group.18
The protocol and informed consent forms were reviewed and
approved by the KEMRI local and national scientiﬁc steering
committees and the KEMRI National Ethical Review Committee
and the institutional review boards (IRBs) of the CDC and the
AERAS Global TB Vaccine Foundation.
3. Results
Through the HDSS database, 5541 adolescents were identiﬁed
for screening; parental consent and minor assent was given for
5241 (94.6%). Of the 300 individuals not giving consent, 222 (74%)
had not been found at home during home visits by trained ﬁeld
workers. Of the participants consenting to participate in the study,
236 (4.5%) did not turn up for study procedures. Thus, 5004 (90.3%)ent and TB screening.
Table 1
A comparison of the demographic characteristics of adolescents enrolled into the study with those of the general population of adolescents in the study area
Study participants Non-study participants
from all clusters
OR CI
Age, years Mean 14.4 (SD 1.9) 15.2 (SD 2.0) p < 0.01
Sex Female 2425 (48.5%) 2886 (51.9%) 0.87 0.81–0.94
Male 2579 (51.5%) 2678 (48.1%)
Residence Rural 4729 (94.5%) 4671 (87.0%) 0.30 0.26–0.35
Urban 275 (5.5%) 893 (16.0%)
OR, odds ratio; CI, conﬁdence interval; SD, standard deviation.
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(Figure 1).
Among the enrolled adolescents, 2579 (52%) were male; the
mean age was 14.0 years (standard deviation 1.9 years), and most
(4692, 93.8%) were enrolled in school and lived in the rural areas
(4729, 94.5%). Compared with the general population of adoles-
cents in the HDSS area, study participants were more likely to be
male and live in a rural area (Table 1). At enrolment, 1960 (39.2%)
adolescents were found to have suspected TB based on a history of
symptoms (515, 10.3%), contact with a TB case (144, 7.4%), and/or a
positive TST (1544/4808 read, 32.1% positive) (Figure 2). There was
a trend towards increasing Mantoux positivity by age. Comparing
adolescents aged 12 years to those aged 18 years, 26.2% and 39.7%
were Mantoux-positive, respectively (Table 2).
A minority of participants (12.7%) had more than one criterion
for TB investigation. All suspected TB cases underwent a chest
X-ray examination and 93 (4.7%) had an abnormal chest X-ray, of
which 20 (1.0%) were classiﬁed as consistent with TB. Of suspected
TB cases, 1862 (95.0%) and 1686 (86.0%) provided a spot and an
early morning sputum, respectively. The majority of suspected TB
cases agreed to HIV testing and 23 were HIV-infected (1.2%).
A total of 16 deﬁnite and 18 probable cases were identiﬁed,
yielding a cluster-adjusted TB prevalence estimate of 6.8/1000
(95% CI 4.1–9.5) for deﬁnite and probable TB combined (design
effect 1.04) and 3.2/1000 (95% CI 1.9–4.5) for deﬁnite TB. Of the
16 deﬁnite TB cases, 15 (93.8%) were smear-negative. Most TB
cases were TST-positive (30/34, 88.2%). Very few of the TB cases
identiﬁed gave a history of symptoms suggestive of TB 6/34 (17.7%)
and none reported a history of a household contact with TB. There
was no trend of an increasing prevalence of TB with age, neither for
deﬁnite nor for all types of TB (Table 3).
In the laboratory at that time, there was a TB laboratory cross-
contamination rate of 0.03% as measured by artiﬁcial sputumFigure 2. Distribution of suspected TB cascultures, well within the 1.1% standard.19 Four participants had a
positive smear; two were culture-negative, one grew non-
tuberculous mycobacteria (NTM), and one was both smear- and
culture-positive. A total of 242/5004 (4.8%) adolescents had
positive cultures identiﬁed as NTMs and were sputum smear-
negative. Twenty-ﬁve new TB cases were notiﬁed in adolescents
aged 12–18 years by the TB control program in the study area
during 2010. The population of adolescents aged 12–18 years was
24 840, giving a case notiﬁcation rate of 101/100 000. The rate at
which new TB cases were detected as expressed by the PDR was
0.13 (95% CI 0.03–3.7) cases detected per person-year for all types
of TB. No risk factors for prevalent TB were identiﬁed (Table 4). All
deﬁnite TB cases were TST-positive and the majority had no chest
X-ray abnormalities (Table 5). All of the 18 probable TB cases had
chest X-ray abnormalities consistent with TB, 14 were TST-
positive, and four had symptoms of TB (Table 5).
4. Discussion
We found a high prevalence of TB among adolescents, with a
deﬁnite TB prevalence rate of 3.2/1000 and a total prevalence of
6.8/1000 population. Similar studies conducted in South Africa20
and Uganda21 to estimate the prevalence of TB among 12–18-year-
old adolescents in preparation for future TB vaccine trials, found a
prevalence of 3/1000 in South Africa for smear/culture-positive TB
and 1.6/1000 for all TB in Uganda. Our prevalence is comparable to
that found in the Western Cape, South African study, but more than
double that found in rural Uganda, which neighbors Kenya. This
high prevalence far exceeds that of the case notiﬁcation rate in the
region and suggests that efforts are needed to improve TB case
detection in the population. Future studies should consider the
inclusion of even younger children to better characterize the
burden of TB disease among adolescents. These ﬁndings suggestes identiﬁed at enrolment (N = 1960).
Table 2
Comparing tuberculin skin test positivity by age
Age, years Number TST-positive
(10 mm)
Total % TST-positive
12 265 1012 26.2%
13 256 874 29.3%
14 244 824 29.6%
15 221 689 32.1%
16 260 658 39.5%
17 178 449 39.6%
18 120 302 39.7%
TST, tuberculin skin test.
Table 3
Prevalence rates of all and deﬁnite TB cases by age
Age All TB cases TB
prevalence,
per 1000
Culture-conﬁrmed
TB cases
TB
prevalence,
per 1000
Yes No Total Yes No Total
12 6 1042 1050 5.7 2 1048 1050 1.9
13 7 884 892 7.8 3 889 892 3.4
14 5 842 847 5.9 3 844 847 3.5
15 6 709 715 8.4 4 711 715 5.6
16 5 688 694 7.2 2 692 694 2.9
17 4 478 482 8.3 2 480 482 4.1
18 1 323 324 3.1 0 324 324 0
Total 34 4966 5004 6.8 16 4988 5004 3.2
TB, tuberculosis.
Table 5
Clinical characteristics of prevalent tuberculosis cases, Siaya District, western
Kenyaa
TB case Symptoms
(n = 6)
TST
(n = 30)
CXR
(n = 20)
Smear
(n = 1)
Culture
(n = 16)
1  + +  +
2  +   +
3 + +   +
4  +   +
5  +   +
6  +   +
7  +   +
8  +  + +
9  +   +
10  +   +
11 + +   +
12  +   +
13  +   +
14  + +  +
15  + +  +
16  +   +
17  + +  
18 +  +  
19  + +  
20  + +  
21  + +  
22  + +  
23  + +  
24  + +  
25   +  
26  + +  
27  + +  
28 + + +  
29 +  +  
30  + +  
31  + +  
32  + +  
33  + +  
34 +  +  
TB, tuberculosis; TST, tuberculin skin test; CXR, chest X-ray.
a All cases were HIV-negative and gave no history of household contact with a TB
case; +, characteristic present; , characteristic absent. All the culture-positive
cases were deﬁned as deﬁnite cases, and all the culture-negative cases were deﬁned
as probable cases.
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12 years.22–24 The high PTB prevalence was not explained by HIV,
the prevalence of which was quite low among these young
adolescents. The high HIV prevalence in the study area, coupled
with a high burden of TB disease among HIV-infected individuals,
might still be a major driver of TB transmission to adolescents
through adult community contacts.
The very low patient diagnostic rate of 0.13 cases detected per
person-year for all types of TB indicates that the TB control
program is performing suboptimally, presumably because preva-
lent cases are not always symptomatic or smear-positive, and
detecting smear-negative TB is a major challenge for the program
with currently used tools. With the prevalence of TB this high, the
incidence may be high as well. Obtaining direct incidence
estimates through a cohort of adolescents followed up for at least
a year, as we are currently performing, would provide incidence
estimates useful for the sample size calculations required for
adolescent TB vaccine trials.Table 4
Characteristics of prevalent tuberculosis cases, Siaya District, western Kenya
TB cases (cases
Deﬁnite TB cas
Male Yes 8 (3.1) 
No 8 (3.3) 
Urban residence Yes 1 (3.7) 
No 15 (3.2) 
Enrolled in school Yes 15 (3.2) 
No 1 (3.2) 
Orphaned Yes 5 (6.6) 
No 11 (2.6) 
New resident Yes 5 (4.2) 
No 11 (2.9) 
BCG scar present Yes 12 (2.9) 
No 4 (4.5) 
Socio economic status (SES) score 7.2 (3.2) 
TB, tuberculosis; BCG, bacille Calmette–Gue´rin.The younger age group enrolled in this study (12–18 years) had
comparable TB rates to those from the partly overlapping, but older
age group of 15–24 years in the previously reported prevalence
survey in this area.12 That survey found a prevalence rate of 3.7/
1000 among females and 1.8/1000 among males. Within the
current study, there was no association between age or gender and
prevalence. This lack of association could be due to a small sample per 1000)
es (n = 16) Probable TB cases (n = 18) Total
(n = 5004)
13 (5.0) 2576
5 (2.1) 2424
1 (3.7) 273
17 (3.6) 4727
17 (3.6) 4678
1 (3.2) 317
0 (0) 760
18 (4.3) 4235
7 (5.8) 1204
11 (2.9) 3796
13 (3.2) 4096
5 (5.7) 885
6 (2.8) 7 (2.7)
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prevalence of TB.
The majority of the TB cases found were smear-negative,
including most of the culture-conﬁrmed cases. The results of TB
culture can be trusted, as indicated by the very low cross-
contamination rate of 0.03%. The majority of the deﬁnite and
probable TB cases had a positive TST, conﬁrming the utility of this
test for screening and active case ﬁnding. All of the probable cases
had a chest X-ray consistent with TB, but were likely found quite
early in the disease progression as evidenced by the low number of
cases with symptoms. A large number of cultures grew NTM. This
indicates the value of culture conﬁrmation and speciation in a
community with a very high burden of NTM to ensure proper
diagnosis and appropriate treatment for TB. The clinical signiﬁ-
cance of this high NTM burden and their implications for immune
responses to new TB vaccines need to be explored further.25,26
The study had some limitations, in particular with respect to the
enrolment of out-of-school youth. At the time of conducting the
study, data from the Siaya District Education Ofﬁce indicated that
only approximately 40% of adolescents aged 12–18 years in the
target area of Siaya District were enrolled in schools. If TB rates
were higher in out-of-school youth, TB prevalence may have been
underestimated among adolescents. This is similar to the Western
Cape, South African study, which enrolled mainly in-school youth
and might also have underestimated the prevalence of TB among
adolescents in that population.20 Moreover, since school enrol-
ment was found to decrease with age, we may have obscured an
increasing prevalence with age. The decrease in older age groups is
ascribed to outmigration by older adolescents completing school
and leaving the study area and post-primary adolescents going to
secondary schools outside the study area.
In conclusion, our study suggests that adolescents should be
treated as a priority for TB control efforts. The national TB program
should develop strategies to improve case detection among
adolescents, in particular those with smear-negative TB, for
instance through wider use of Xpert MTB/RIF. Xpert MTB/RIF is
an automated PCR-based assay, with high sensitivity and a turn-
around time of under 2 h.27 Future studies should explore the
utility of adding Xpert MTB/RIF as an additional tool for the
identiﬁcation of cases.
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